Browsing "Hematology-Oncology" by Journal : Journal of clinical oncology
Showing results 1 to 14 of 14
| Pub Year | | Title | Author(s) |
| 2019 | | A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746) | 강석윤 |
| 2018 | | An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09) | 이현우 |
| 2019 | | Does the extent of brain metastasis affect outcome of non-small cell lung cancer patients treated with chemotherapy? | 강석윤, 안미선, 이현우, 최용원, 최진혁 |
| 2020 | | Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931) | 안미선 |
| 2018 | | Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma. | 이현우 |
| 2015 | | Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. | 최진혁 |
| 2024 | | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | 이현우 |
| 2020 | | Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) | 안미선 |
| 2022 | | Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07 | 강석윤 |
| 2013 | | Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. | 강석윤 |
| 2021 | | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | 최진혁 |
| 2018 | | Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy | 강석윤, 안미선, 이현우, 최용원, 최진혁 |
| 2018 | | Should combination chemotherapy be used in all advanced gastric cancer patients? | 강석윤, 안미선, 이현우, 최용원, 최진혁 |
| 2019 | | The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study | 강석윤 |
1
